HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Adenosine 5'-diphosphate-induced platelet aggregation in uremia shows resistance to inhibition by the novel nitric oxide donor GEA 3175 but not by S-nitroso-N-acetylpenicillamine.

Abstract
Both bleeding and thrombosis are complications of uremia in patients on regular hemodialysis. An excessive endogenous formation of the vasodilator and platelet inhibitor nitric oxide (NO) has been proposed to contribute to the bleeding defect. Since exposure to pharmacological donors of NO, nitrovasodilators, can cause tolerance to NO, we investigated whether platelets from uremic patients on regular hemodialysis are influenced differently by NO donors than platelets from healthy subjects. A frequently used S-nitrosothiol, S-nitroso-N-acetylpenicillamine (SNAP), was compared to a recently synthezised mesoionic oxatriazole derivate, GEA 3175, regarding its capacity to inhibit adenosine 5'-diphosphate (ADP)-induced platelet aggregation in vitro. The final products of NO production, nitrite + nitrate, were found to be significantly increased in uremic patients. The capacity to inhibit platelet aggregation by SNAP was only slightly different between the groups. However, GEA 3175 showed a significantly marked and reduced capacity to inhibit aggregation of uremic platelets compared to controls. Interactions of erythropoietin (EPO) with NO have earlier been reported. Addition of EPO to platelets from healthy donors in vitro did not significantly influence the NO donor capacity to inhibit platelet aggregation, but showed a tendency to enhance the effect of SNAP while the effect of GEA 3175 was inhibited. These results suggest compound-specific resistance to NO donors in uremic platelet activation.
AuthorsP A Whiss, R Larsson
JournalHaemostasis (Haemostasis) 1998 Sep-Oct Vol. 28 Issue 5 Pg. 260-7 ISSN: 0301-0147 [Print] Switzerland
PMID10420076 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • GEA 3175
  • Nitric Oxide Donors
  • Platelet Aggregation Inhibitors
  • Triazoles
  • Erythropoietin
  • Adenosine Diphosphate
  • S-Nitroso-N-Acetylpenicillamine
  • Penicillamine
Topics
  • Adenosine Diphosphate (antagonists & inhibitors)
  • Aged
  • Aged, 80 and over
  • Case-Control Studies
  • Dose-Response Relationship, Drug
  • Drug Resistance
  • Erythropoietin (therapeutic use)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Nitric Oxide Donors (therapeutic use)
  • Penicillamine (analogs & derivatives, therapeutic use)
  • Platelet Aggregation Inhibitors (therapeutic use)
  • S-Nitroso-N-Acetylpenicillamine
  • Triazoles (therapeutic use)
  • Uremia (blood, drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: